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Abstract
Aim The expression of pro-apoptotic (Bax) and anti-
apoptotic (mutated p53, Bcl-2, Bclxl) proteins was
determined retrospectively using immunohistochemistry
in pre-treatment biopsy samples from patients with rectal
cancer treated with or without preoperative chemoradi-
ation to investigate their role as prognostic markers and
indicators of radiochemosensitivity.
Method Biopsy samples from 67 patients operated for
stage II ⁄ III rectal cancer and enrolled in an active follow-
up programme were examined 8–10 years after surgery.
Thirty-three had been treated with immediate surgery
followed, in selected cases, by adjuvant postoperative
chemoradiation. Thirty-four had preoperative chemora-
diation. Immunohistochemical staining was carried out
using an automated immunostainer on sections of
paraffin-embedded tissue.
Results Independent prognostic factors for rectal cancer
death were pN status (hazard ratio 3.82; 95% CI 1.67–
8.73) and a high level of Bclxl positivity (hazard ratio
4.75; 95% CI 2.10–10.72) according to multivariate
regression analysis by stepwise selection. Bax expression
was associated with downstaging and higher survival in
irradiated patients (P = 0.0004).
Conclusion Pretreatment evaluation of apoptotic Bax
and anti-apoptotic Bclxl factors in biopsy samples of stage
II ⁄ III rectal cancers may be helpful in selecting tumours
that will respond to chemoradiation or in identifying
patients who will have limited benefit from chemoradi-
ation and should therefore be selected for a more
aggressive systemic regimen.
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What is new in this paper
The expression of pro-apoptotic and anti-apoptotic pro-
teins was examined in pretreatment biopsy samples of
patients with rectal cancer treated with or without pre-
operative chemoradiation to investigate their possible
role as prognostic indicators of radiochemosensitivity.
Introduction
Preoperative chemoradiation is increasingly used in the
treatment of operable but advanced (clinical T3) rectal
cancer. The aim is to reduce local recurrence, improve
survival and allow a larger number of sphincter-saving
procedures. Despite the occurrence of adverse effects,
including grade II ⁄ III toxicity (NCI scale), satisfactory
results have been reported in single-centre experiences
and clinical trials [1,2]. The tumour regression and so-
called ‘downstaging’ obtained by neoadjuvant treatment
in 50–60% of cases appear to be related to a better
oncological outcome and increased number of sphincter-
saving operations [3–6].
However, there is a limited or no response to
chemoradiation in a significant number of patients
(40–50%), and the prognosis seems to be particularly
poor [5–8]. Cancer patients with persisting positive
lymph nodes after chemoradiation (more than 50% of
N+ tumours identified by preoperative endorectal ultra-
sound) have an unfavourable outcome [6,7]. Thus a
number of patients with stage II ⁄ III low rectal cancer will
not benefit from preoperative chemoradiation, with 25–
30% of them experiencing toxicity. It would be useful to
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have biological markers of prognostic significance and of
sensitivity to chemoradiation to avoid unnecessary and
potentially harmful complications in these patients [9].
Many biomolecular prognostic markers and markers
of sensitivity to neoadjuvant treatment in rectal cancer
have been identified and some, like endothelial growth
factor receptor microsatellite instability, wild K-ras, are
increasingly used in clinical practice [10–13].
Several studies have aimed to evaluate the usefulness
of markers of apoptosis, the mechanism controlling the
development and progression of a cancer, in relation to
the disruption of cell cycle control and programmed cell
death [10]. The disruption of this regulatory mechanism,
particularly regarding cell death signalling, has a major
impact on the resistance of malignant tumours to
radiotherapy and chemotherapy [14].
The apoptotic process is regulated by various proteins
at different levels. Proteins of the Bcl-2 family are central
regulators of apoptosis initiated at the mitochondrial
level [15,16]. The Bcl-2 family includes anti-apoptotic
(Bcl-2 and Bclxl) and pro-apoptotic proteins (Bax). The
balance and interactions between pro-apoptotic and anti-
apoptotic proteins regulates the apoptotic machinery
[17].
Another protein involved in the apoptotic process is
the p53 tumour suppressor gene. This molecule plays a
central role in promoting genomic stability and tissue
homeostasis [18]. Wild-type p53 induces apoptosis in
damaged cells, although the marker usually detected with
immunohistochemistry in clinical studies is the mutated
form which has lost this activity. Mutated p53 suppresses
apoptosis and confers chemotherapy and radiotherapy
resistance to cancer cells [18].
The present study examined the expression of one
pro-apoptotic (Bax) and three anti-apoptotic (p53, Bcl-2,
Bclxl) proteins using immunohistochemistry in pretreat-
ment biopsy samples from preoperatively non-irradiated
and irradiated rectal carcinoma patients. Patients were
operated on in a period in which neoadjuvant chemora-
diation for T3 cancer was not routinely adopted in our
department. The aim was to investigate the role of the
proteins as potential indicators of resistance or sensitivity
to preoperative chemoradiation.
Method
The study was approved by the ethical committee of the
Azienda Ospedaliera Universitaria Careggi, Florence.
Pretreatment biopsy samples from the tumour from 67
consecutive patients (44 men) with adenocarcinoma of
the rectum, treated over a 3-year period, were examined
by immunohistochemical staining 8–10 years after
surgery.
All patients had had a tumour located at less than
12 cm from the anal verge, classified at presentation as T3
by clinical examination, endorectal sonography, abdomi-
nopelvic CT scan and, at times, MRI with endorectal coil.
Lymph nodal evaluation was not performed at that time.
Preoperative chemoradiation was offered to all
patients after explaining the goals and risks of neoadju-
vant vs a more selective adjuvant treatment. Thirty-three
patients (group I) preferred to undergo immediate
surgery followed by adjuvant chemoradiation when
indicated, while 34 (group II) accepted preoperative
neoadjuvant chemoradiotherapy. Eventually all patients
were operated on undergoing a curative total mesorectal
excision. Patients in group II were operated on
6–9 weeks after the completion of treatment. Patients
in group I with positive lymph nodes received adjuvant
chemoradiation.
Preoperative chemoradiation therapy fields included
the primary tumour, the adjacent lymph node drainage
area in the pelvis and the regional nodes along the
superior haemorrhoidal vessels. The tumour dose was
45 Gy delivered in 25 daily fractions of 1.8 Gy. Chemo-
therapy consisted of fluorouracil (5-FU, 375 mg ⁄ m2
bolus daily for 5 days) and leucovorin (LV, 10 mg ⁄ m2
daily for 5 days). These were administered concurrently
during the first 5 days and on days 29–33 of radiation
therapy.
Postoperative adjuvant chemoradiation was started
4–6 weeks after surgery with chemotherapy given for two
cycles every 28 days in the same dosage as above. After
two cycles of 5-FU plus LV, radiotherapy was initiated in
daily fractions of 2 Gy over 5 weeks to a total dose of
54 Gy. All patients with positive nodes in groups I and II
were planned to receive four extra cycles of postoperative
chemotherapy. Follow-up included clinical examination,
CEA monitoring, colonoscopy and CT of abdomen and
thorax. One patient in group II died in the perioperative
period and was excluded from the study.
Immunohistochemical assay
Staining was conducted using an automated immuno-
stainer (Ventana NexES; Ventana MedicalSystems,
Tucson, Arizona, USA) on 4-lm thick sections of
paraffin-embedded tissue. Sections were deparaffinized
in xylene and rehydrated in a descending ethanol series.
Endogenous peroxidase activity was blocked by immer-
sion for 10 min in phosphate-buffered saline (pH 7.4).
The primary antibodies used in the study were as follows:
(1) anti-p53 monoclonal antibody (dilution 1:100; clone
DO-7, Dako SA, Glostrup, Denmark); (2) anti-Bcl-2
monoclonal antibody (dilution 1:50; clone l24, Dako)
recognizing mutant protein; (3) anti-Bclxl monoclonal
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antibody [dilution 1:50 (Zymed, San Francisco, Califor-
nia, USA) in 0.3% hydrogen peroxide in methanol
solution, followed by a single wash in phosphate]; and
(4) anti-Bax polyclonal antibody (dilution 1:50; code
A3533, Dako). The immunostaining was developed
using 3,3¢-diaminobenzidine as chromogen. Appropriate
positive and negative controls were added to each
automated immunohistochemistry run to confirm anti-
body specificity.
After immunostaining, in each case the entire section
was examined by light microscopy at a magnification
100· by one pathologist (LM) without knowledge of the
patient’s outcome. The percentage of immunostained
cells was originally recorded as follows: 0 (none or
< 10%); 1 + (10–25%); 2 + (26–50%); 3 + (51–75%);
4 + (76–100%). To simplify statistical analysis, however,
these were reduced to three groups: negative (none or
< 10%), medium positive (10–50%) or high positive
(> 50%). The different levels of Bclxl are shown in
Fig. 1 and the high levels of Bcl-2, Bax and p53 in Fig. 2.
Statistical analysis
For regression analyses, we used for each marker a
medium positivity level and a high positivity level which
were compared with the negative level. Selected charac-
teristics were compared in the groups using Fisher’s exact
test, the chi squared or the Mann–Whitney test as
appropriate. Survival was calculated from the date of the
first treatment to the date of the last follow-up or death.
Local disease-free survival was calculated from the date of
first treatment to the date of recurrence. Crude survival
was estimated using the Kaplan–Meier method and
differences between patient groups were assessed by the
log-rank test. Comparisons in survival were made using
the Cox proportional hazards regression model. Esti-
mated relative risks of dying were expressed as adjusted
hazard ratios (HRs) with 95% CI. A regression model
with stepwise selection was performed to identify the
major significant predictors of death. Statistical results
were considered significant at a P-value of < 0.05. All
statistical tests were performed using SAS software
(Florence, Italy).
Results
Preoperative assessment correctly staged T3 cancers in 31
(94%) patients in group I (n = 33). One patient had a T2
and another a T4 cancer. In group II (n = 33) the results
of pathological examination of the resected specimen
showed eight T0 (24%), one TI (3%), eight T2 (24%), 16
T3 (49%) tumours. The individual characteristics of the
66 patients, nodal status and results of treatments are
shown in Table 1. Twenty-two patients in group I had
(a) (b) (c)
Figure 1 Examples of three levels of Bclxl
immunostaining: (a) negative (none or
< 10%); (b) medium positive (10–50%);
(c) high positive (> 50%).
(a) (b) (c)
Figure 2 Examples of high positivity
immunostaining: (a) Bcl-2; (b) Bax; (c)
p53.
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surgery alone, 11 had postoperative chemoradiation
because of lymph node involvement (N+), in two of
them there were infiltration of circular resection margin.
Of the 66 patients, 43 (65%) were men. The mean age
was 67 (SD ± 9) years. Patients in group I were younger
(P = 0.004). There were no differences between the
groups in the distance of the tumour from the anal verge
or in the proportion of sphincter-sparing procedures
(86% vs 75%). No patient was lost to follow-up. At the
last follow-up (mean 105.5 ± 39.6 months), 27 (40.9%)
patients had died. The incidence of local recurrence (2%
vs 4%; P = 0.69), distant metastases (13% vs 7%;
P = 0.09) and survival (P = 0.13) was not statistically
different between the groups. The pretreatment distri-
bution of markers was also similar, apart from the absence
of patients with a high level of positivity for Bcl-2 in the
chemoradiation group (Table 2).
In group I, despite the disparity in mortality between
11 N+ and 22 N) patients (45.5% vs 22.7%) the differ-
ence was not significant (Table 3). However, a statisti-
cally significantly lower survival was observed in patients
with high levels of positivity for p53 (P = 0.003), Bcl-2
(P = 0.01) and Bclxl (P = 0.003). A borderline associa-
tion between Bax expression and improved survival was
also seen (P = 0.06).
Multivariate regression analysis by stepwise selection
showed a high level of positivity of Bclxl (HR 3.99; 95%
CI 1.03–1542) and p53 (HR 4.99; 95% CI 1.16–21.44)
to be significant independent prognostic factors for lower
survival (Table 3).
In node-negative patients of group I (n = 22) no
significant relationship between the level of the markers
and survival was observed. On the contrary, in node-
positive patients of the same group (n = 11) a high
expression of Bclxl was associated with a significantly
higher risk of death (P = 0.01). There was an almost
statistically significant (P = 0.075) relationship between
Bax level and node-positive patients with lower mortality.
In group II, pN status, p53 and Bclxl high level
expression emerged as significant predictors of death
(P = 0.0001, P = 0.03 and P = 0.004), while Bax
Table 1 Distribution of 66 rectal cancer patients according to







Male 22 (66.7) 21 (63.6) 1.0
Female 11 (33.3) 12 (31.8)
Age, years
£ 55 – 8 (24.2) 0.01
56–65 9 (27.3) 11 (33.3)
66–75 14 (42.4) 9 (27.3)
> 75 10 (30.3) 5 (15.2)
Mean age (± SD) 70.5 (± 7.2) 63.6 (± 9.4) 0.004
pN
N0 22 (66.7) 23 (69.7) 0.58
N1 8 (24.2) 9 (27.3)
N2 3 (9.1) 1 (3.0)
Surgery
AP 5 (15.2) 8 (24.2) 0.04
AR 8 (54.5) 8 (24.2)
CA 10 (30.3) 17 (51.6)
Distance from anal verge (cm)
‡ 6 13 (39.4) 7 (21.2) 0.18
< 6 20 (60.6) 26 (78.8)
Local recurrence
Negative 29 (87.9) 31 (93.9) 0.69
Positive 4 (12.1) 2 (6.1)
Distant metastasis
Negative 26 (78.7) 20 (60.6) 0.09
Positive 7 (21.3) 13 (39.4)
Status
Alive 23 (69.7) 16 (48.5) 0.13
Dead 10 (30.3) 17 (51.5)
Total 33 (50.0) 33 (50.0)
AP, abdominoperineal excision; AR, anterior resection; CA,
coloanal anastomosis.
*P-value from Fisher exact test, chi squared for trend or Mann–
Whitney test, as appropriate.
Table 2 Distribution of 66 patients with rectal cancer according






Negative 9 (27.3) 7 (21.2) 0.61
Medium positive 13 (39.4) 17 (51.5)
High positive 11 (33.3) 9 (27.3)
Bax
Negative 17 (51.5) 9 (27.3) 0.10
Medium positive 12 (36.4) 13 (39.4)
High positive 4 (12.1) 11 (33.3)
Bcl-2
Negative 8 (24.2) 18 (54.6) 0.03
Medium positive 13 (39.4) 15 (45.4)
High positive 12 (36.4) 0
Bclxl
Negative 10 (30.3) 17 (51.5) 0.21
Medium positive 14 (42.4) 9 (27.3)
High positive 9 (27.3) 7 (21.2)
Total 33 (50.0) 33 (50.0)
Expression was classified as negative (none or < 10% of tumour
cells stained), medium positive (10–50% of tumour cells stained)
or high positive (> 50% of tumour cells stained).
*P-value from chi squared.
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expression was associated with higher survival
(P = 0.0004). Multivariate regression analysis by stepwise
selection indicated that pN status (HR 5.95; 95% CI
1.92–18.46) and a high level of Bclxl positivity (HR 3.51;
95% CI 1.16–10.59) were significant independent prog-
nostic factors of death from rectal cancer.
Table 3 Clinico-pathological characteristics and marker expression in relation to specific survival in the two groups of patients.
At start
Follow-up
Log-rank test* HR (95% CI)No. of deaths Specific survival
Group I
pN
N0 22 5 75.8 (51.1–89.2) 0.13 –
N1 8 3 58.3 (18.0–84.4)
N2 3 2 33.3 (0.9–77.4)
p53
Negative 9 2 77.8 (36.5–93.9) 0.003 1
Medium positive 13 1 92.3 (56.6–98.9) 0.37 (0.03–4.11)
High positive 11 7 25.3 (4.1–55.2) 4.94 (1.01–24.34)
Bax
Negative 17 8 47.1 (20.9–69.5) 0.06 –
Medium positive 12 2 82.5 (46.1–95.3)
High positive 4 0 100
Bcl-2
Negative 8 0 100 0.01 –
Medium positive 13 3 76.9 (44.2–91.9) 1
High positive 12 7 33.0 (8.4–60.9) 3.44 (0.88–13.44)
Bclxl
Negative 10 1 87.5 (38.7–98.1) 0.003 1
Medium positive 14 3 77.9 (45.9–92.3) 2.26 (0.24–21.73)
High positive 9 6 25.4 (3.8–56.4) 11.64 (1.39–97.31)
Total 33 10 67.3 (47.6–81.0)
Group II
pN
N0 23 9 59.8 (37.37–82.4) 0.0001 1
N1 9 7 14.8 (0–40.9) 6.49 (2.17–19.41)
N2 1 1 0 (–) 23.70 (2.19–256.7)
p53
Negative 7 2 68.6 (32.1–100) 0.03 1
Medium positive 17 7 54.4 (28.9–79.9) 1.40 (0.29–6.77)
High positive 9 8 16.7 (0–44.4) 4.27 (0.90–20.41)
Bax
Negative 9 7 16.7 (10–44.4) 0.0004 1
Medium positive 13 6 69.6 (33.3–87.7) 0.16 (0.05–0.53)
High positive 11 4 46.2 (4.3–88.0) 0.13 (0.03–0.49)
Bcl-2
Negative 18 7 51.2 (22.0–80.4) 0.11 1
Medium positive 15 10 37.5 (12.1–62.9) 2.16 (0.82–5.70)
High positive – – –
Bclxl
Negative 17 6 54.1 (23.84.3) 0.004 1
Medium positive 9 5 53.3 (19.4–87.3) 1.93 (0.58–6.40)
High positive 7 6 14.3 (0–40.8) 5.96 (1.87–19.02)
Total 33 17 23.9 (2.0–57.9)
*From univariate survival analysis by the Kaplan–Meier method.
From Cox regression analysis.
Reference category.
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When all 66 patients were submitted to multivariate
regression analysis by stepwise selection, including the
items ‘preoperative chemoradiation’ and ‘postoperative
chemoradiation’, only pN status (HR 3.82; 95% CI 1.67–
8.73) and a high level of Bclxl positivity (HR 4.75; 95%
CI 2.10–10.72) were found to be independent prognos-
tic factors for death from rectal cancer. The survival rate
according to Bclxl expression is shown in Fig. 3.
Analysis of pN status with each marker showed a
significant interaction with a high level of Bclxl positivity
in the whole series (HR I7.10; 95% CI 6.17–47.54), and
also in group analysis (group I: HR 16.3; 95% CI 3.54–
74.86; group II: HR 21.59; 95% CI 2.87–162.57).
Downstaging
Seventeen patients in group I showed a downstaging
effect (from clinical T3 to pathological T2, T1, T0). All
downstaged cases were Bax positive and 15 ⁄ 17 (88.2%)
were p53 positive. Bax positivity was significantly associ-
ated with downstaging (P = 0.001) and longer survival. A
trend toward better survival was also demonstrated by
downstaged patients with a negative or very low expres-
sion of p53 (50% vs 28%). Five-year survival was signif-
icantly better in downstaged patients (log-rank test
P = 0.016) although in the long term this difference
seemed to disappear (log-rank test P = 0.32) (Fig. 4).
Local recurrence
Only six local recurrences were found in the whole series
(four in group I, two in group II), occurring at 23 (6–72)
months. There was no relationship between the incidence
of local recurrence and the level of any of the markers.
Discussion
Despite possible bias due to the small number of patients
in the study, the high level of significance of some of the
results is likely to indicate real associations between the














Yes downstaging (n : 17)
Long rank test: at 5 years P = 0.016; at the end of follow-up P = 0.32
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Figure 4 Kaplan–Meier survival curve for
33 patients in group II according to the
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Figure 3 Kaplan–Meier survival curve for
66 rectal cancer patients according to Bclxl
expression.
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p53 has been the most studied prognostic marker and
predictor of response to chemoradiation in rectal cancer
[18–20]. Various techniques have been used to detect
p53, including immunohistochemistry, single-strand
conformational polymorphism analysis and direct p53
gene sequencing. Immunochemistry has been the most
frequently used method [21]. Regardless of the evalua-
tion method, the correlation between p53 and response
to radiotherapy, rate of local recurrence and disease-free
overall survival observed by some workers [21] has not
been confirmed by others [22,23].
In the present study using univariate analysis, over-
expression of the marker appeared to be significantly
related to worse survival in both groups of patients when
the rate of stained cells exceeded 50%. However, p53
was no longer an independent prognostic factor accord-
ing to multivariate regression analysis of all patients. In
addition, no significant correlation was observed
between p53 expression and response to radiochemo-
therapy even though 88.4% of downstaged patients were
p53 positive.
Results reported in the literature regarding Bax
protein are also controversial. Some authors report that
Bax overexpression in stage Il cancer is a marker of poor
prognosis and higher local recurrence [20], but others
have found no association [20,24]. In more recent
studies, however, Bax appeared to be a very reliable
predictive marker for therapeutic response to preopera-
tive radiochemotherapy [25,26] with a higher expression
in complete than in partial responders. In other reports a
high expression of Bax protein and low expression of p53
were related to a better prognosis in stage III cancer [27]
and, according to univariate and multivariate analysis, Bax
expression was an independent prognostic indicator of
longer local recurrence-free interval and disease-free
survival [28].
Our results are in agreement with the more recent
studies. We found that Bax was positively related with
response to preoperative neoadjuvant chemoradiotherapy
and overall survival (Table 3).
With regard to Bcl-2 our results are similar to data in
the literature [15]. No particular value was found to
predict response to chemoradiation, although some
authors have found that an elevated tissue Bcl-2 ⁄ Bax
ratio is related to increased tumour resistance to adjuvant
radiotherapy [29]. One indication of prognosis was
found in patients having immediate surgery who had a
high rate of Bcl-2 stained cells, according to univariate
analysis. The role of Bcl-2 in patients having chemora-
diotherapy is less clear since in the present study there was
an absence of high expression of this marker in all
patients. This marker may have some prognostic value
but at a much lower strength than other markers.
Bclxl is the least understood marker. This anti-
apoptotic molecule, which seems to protect cancer cells
from wild p53-mediated apoptosis [30], has recently
been identified to be 10 times more effective than Bcl-
2 when expressed in a breast cancer line [31]. In our
experience its role as a prognostic marker was relevant.
According to stepwise-selected multivariate regression
analysis, only pN status and a high level of Bclxl
positivity emerged as independent prognostic factors
for death due to rectal cancer. When we examined the
results separately in groups I and II by multivariate
regression analysis a high level of Bclxl remained the
only significant independent prognostic factor although
it did show a significant interaction with pN status.
In conclusion, a high expression of apoptotic Bax
protein is correlated with a good response to preoperative
chemoradiation and possibly with improved survival.
Improved survival was also observed in N+ patients who
underwent surgery and postoperative adjuvant chemora-
diation.
The anti-apoptotic paralogue Bclxl, when highly
expressed, seems to have such a powerful prognostic
influence on advanced stage II and III rectal cancer
patients treated with or without preoperative chemora-
diation that it overcomes the effect of the other apoptotic
markers and possibly even of lymph node positivity.
When a high expression of Bclxl is combined with lymph
node positivity, the prognosis is particularly poor,
regardless of the type of treatment administered. Since
such patients formed 23% of our entire patient group, it is
of the utmost importance to develop more reliable
methods of preoperative nodal staging and to confirm
the prognostic role of Bclxl in a prospective study.
Patients suspected of being node positive before treat-
ment who have a high expression of Bclxl in a biopsy
specimen should be regarded as being at high risk of a
poor outcome and should be administered more aggres-
sive systemic treatment.
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response to radiotherapy in rectal cancer: a prospective
multilevel analysis. Br J Cancer 2005; 92: 2114–21.
23 Saw RP, Morgan M, Koorey D et al. p53, deleted in
colorectal cancer gene, and thymidylate synthase as predic-
tors of histopathologic response and survival in low, locally
advanced rectal cancer treated with preoperative adjuvant
therapy. Dis Colon Rectum 2003; 46: 192–202.
24 Cascinu S, Graziano F, Catalano V et al. An analysis of p53,
BAX and vascular endothelial growth factor expression in
node-positive rectal cancer. Relationships with tumour
recurrence and event-free survival of patients treated with
adjuvant chemoradiation. Br J Cancer 2002; 86: 744–9.
25 Chang HJ, Jung KH, Kim DY et al. Bax, a predictive marker
for therapeutic response to preoperative chemoradiotherapy
in patients with rectal carcinoma. Hum Pathol 2005; 36:
364–71.
26 Nasierowska-Guttmejer A. The comparison of immunohis-
tochemical proliferation and apoptosis markers in rectal
carcinoma treated surgically or by preoperative radiochemo-
therapy. Pol J Pathol 2001; 52: 53–61.
27 Schelwies K, Sturm I, Grabowski P et al. Analysis of
p53 ⁄ BAX in primary colorectal carcinoma: low BAX protein
expression is a negative prognostic factor in UICC stage III
tumors. Int J Cancer 2002; 99: 589–96.
28 Nehls O, Okech T, Hsieh CJ et al. Low BAX protein
expression correlates with disease recurrence in preopera-
tively irradiated rectal carcinoma. Int J Radiat Oncol Biol
Phys 2005; 61: 85–91.
29 Scopa CD, Vagianos C, Kardamakis D et al. bcl-2 ⁄ bax ratio
as a predictive marker for therapeutic response to radiother-
apy in patients with rectal cancer. Appl Immunohistochem Mol
Morphol 2001; 9: 329–34.
30 Schott AF, Apel IJ, Nunez G et al. Bcl-XL protects cancer
cells from p53-mediated apoptosis. Oncogene 1995; 11:
1389–94.
31 Fiebig AA, Zhu W, Hollerbach C et al. Bcl-XL is qualitatively
different from and ten times more effective than Bcl-2 when
expressed in a breast cancer cell line. BMC Cancer 2006; 6:
213.
C. Fucini et al. Apoptotic proteins as prognostic markers and indicators of radiochemosensitivity
 2011 The Authors
Colorectal Disease  2011 The Association of Coloproctology of Great Britain and Ireland. 14, e64–e71 e71
